{"abstract": "Pfizer said it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u2014 a sign of big pharmaceutical companies\u2019 growing interest in stem cells.", "web_url": "https://dealbook.nytimes.com/2009/12/21/pfizer-acquires-a-stem-cell-therapy/", "snippet": "Pfizer said it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u2014 a sign of big pharmaceutical companies\u2019 growing interest in stem cells.", "lead_paragraph": "Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company \u2014 a sign of big pharmaceutical companies\u2019 growing interest in stem cells, The New York Times\u2019s Andrew Pollack reported.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer Acquires a Stem-Cell Therapy", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Medicine and Health", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Athersys", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}], "pub_date": "2009-12-21T10:13:56+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/7f89cf35-b2dd-5dec-ac09-b550b64c48d3", "word_count": 467, "uri": "nyt://article/7f89cf35-b2dd-5dec-ac09-b550b64c48d3"}